Skip to main content
  • 19 Accesses

Trade Names

Boniva; Bondronate.

Class and Category

Anti-osteoporotic. Bisphosphonate drug class.

Indications

Prevention and treatment of osteoporosis in postmenopausal women, demonstrated to reduce the incidence of new vertebral insufficiency fractures. Also used to treat metabolic bone disease associated with malignancy including hypercalcemia of malignancy and bone metastases of solid tumors.

Dosage

2.5 mg orally once daily, or variable dosing intravenously. Should be used in conjunction with adequate supplemental calcium and vitamin D.

Contraindications

Significant renal insufficiency; pregnancy; hypocalcemia.

Adverse Reactions

Dyspepsia, diarrhea, vomiting, gastritis, allergic reaction.

Drug Interactions

Aminoglycosides may lower serum calcium levels with prolonged administration; concomitant use may have additive effect. Increased risk of hypocalcemia with concomitant use of loop diuretics. Risk of renal dysfunction may be increased with concurrent use of thalidomide in patients...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adami S, et al (2002) Three-monthly 2mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 036

    Google Scholar 

  • Delmas P et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study: Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 037

    Google Scholar 

Download references

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag

About this entry

Cite this entry

(2004). Ibandronate. In: Moreland, L.W. (eds) Rheumatology and Immunology Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29662-X_1315

Download citation

  • DOI: https://doi.org/10.1007/3-540-29662-X_1315

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20625-5

  • Online ISBN: 978-3-540-29662-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics